138 related articles for article (PubMed ID: 21128282)
1. LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer.
Thomasson M; Wang B; Hammarsten P; Dahlman A; Persson JL; Josefsson A; Stattin P; Granfors T; Egevad L; Henriksson R; Bergh A; Hedman H
Int J Cancer; 2011 Jun; 128(12):2843-52. PubMed ID: 21128282
[TBL] [Abstract][Full Text] [Related]
2. Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients.
Hammarsten P; Karalija A; Josefsson A; Rudolfsson SH; Wikström P; Egevad L; Granfors T; Stattin P; Bergh A
Clin Cancer Res; 2010 Feb; 16(4):1245-55. PubMed ID: 20145160
[TBL] [Abstract][Full Text] [Related]
3. LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix.
Hedman H; Lindström AK; Tot T; Stendahl U; Henriksson R; Hellberg D
Acta Oncol; 2010 Aug; 49(6):812-5. PubMed ID: 20553099
[TBL] [Abstract][Full Text] [Related]
4. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
5. LRIG1 expression in colorectal cancer.
Ljuslinder I; Golovleva I; Palmqvist R; Oberg A; Stenling R; Jonsson Y; Hedman H; Henriksson R; Malmer B
Acta Oncol; 2007; 46(8):1118-22. PubMed ID: 17851870
[TBL] [Abstract][Full Text] [Related]
6. LRIG1 is a prognostic biomarker in non-small cell lung cancer.
Kvarnbrink S; Karlsson T; Edlund K; Botling J; Lindquist D; Jirström K; Micke P; Henriksson R; Johansson M; Hedman H
Acta Oncol; 2015; 54(8):1113-9. PubMed ID: 25813475
[TBL] [Abstract][Full Text] [Related]
7. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
Di Lorenzo G; Tortora G; D'Armiento FP; De Rosa G; Staibano S; Autorino R; D'Armiento M; De Laurentiis M; De Placido S; Catalano G; Bianco AR; Ciardiello F
Clin Cancer Res; 2002 Nov; 8(11):3438-44. PubMed ID: 12429632
[TBL] [Abstract][Full Text] [Related]
8. Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1.
Yi W; Holmlund C; Nilsson J; Inui S; Lei T; Itami S; Henriksson R; Hedman H
Exp Cell Res; 2011 Feb; 317(4):504-12. PubMed ID: 21087604
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.
Yan Z; Jiang J; Li F; Yang W; Xie G; Zhou C; Xia S; Cheng Y
Oncol Rep; 2015 Apr; 33(4):1791-8. PubMed ID: 25695283
[TBL] [Abstract][Full Text] [Related]
10. Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy.
Wang Q; Diao X; Sun J; Chen Z
Urol Oncol; 2013 Apr; 31(3):312-7. PubMed ID: 21367627
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer.
Vis AN; Noordzij MA; Fitoz K; Wildhagen MF; Schröder FH; van der Kwast TH
J Urol; 2000 Dec; 164(6):2156-61. PubMed ID: 11061947
[TBL] [Abstract][Full Text] [Related]
12. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
[TBL] [Abstract][Full Text] [Related]
13. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
Fleischmann A; Schlomm T; Huland H; Köllermann J; Simon P; Mirlacher M; Salomon G; Chun FH; Steuber T; Simon R; Sauter G; Graefen M; Erbersdobler A
Clin Cancer Res; 2008 Dec; 14(23):7838-42. PubMed ID: 19047112
[TBL] [Abstract][Full Text] [Related]
14. Low p27 expression predicts poor disease-free survival in patients with prostate cancer.
Yang RM; Naitoh J; Murphy M; Wang HJ; Phillipson J; deKernion JB; Loda M; Reiter RE
J Urol; 1998 Mar; 159(3):941-5. PubMed ID: 9474188
[TBL] [Abstract][Full Text] [Related]
15. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
16. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors.
Guo D; Nilsson J; Haapasalo H; Raheem O; Bergenheim T; Hedman H; Henriksson R
Acta Neuropathol; 2006 Mar; 111(3):238-46. PubMed ID: 16532360
[TBL] [Abstract][Full Text] [Related]
17. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
[TBL] [Abstract][Full Text] [Related]
18. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity.
Goldoni S; Iozzo RA; Kay P; Campbell S; McQuillan A; Agnew C; Zhu JX; Keene DR; Reed CC; Iozzo RV
Oncogene; 2007 Jan; 26(3):368-81. PubMed ID: 16847455
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
20. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
